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ABSTRACT
Objective: To compare the effectiveness and cost-
effectiveness among generic and branded statins in routine
clinical practice.
Methods: Retrospective database study of patients, 18+,
who were newly prescribed statin therapy. Statin effectiveness
and cost-effectiveness in reducing low-density lipoprotein
cholesterol (LDL-C) and attaining LDL-C goals were
evaluated.
Results: Of 10,421 eligible patients, % LDL-C reduction
was signiﬁcantly greater (P < 0.001) with rosuvastatin
(-31.6%) than other statins (-13.9 to -21.9%). Percentage
of patients at moderate/high risk attaining LDL-C goal was
higher (P < 0.001) for rosuvastatin (76.1%) versus other
statins (57.6–72.6%). Rosuvastatin was more effective and
less costly than atorvastatin. Among generic statins, simvas-
tatin required >61% discount to branded price to achieve
similar cost-effectiveness as generic lovastatin.
Conclusions: In clinical practice, rosuvastatin is more effec-
tive and less costly in lowering LDL-C and LDL-C goal
attainment compared with atorvastatin. Simvastatin was
more cost-effective compared with lovastatin if >61% dis-
count to branded price was achieved.
Keywords: ATP III goal attainment, cost-effectiveness, LDL
reduction, real-world effectiveness, rosuvastatin.
Introduction
Coronary heart disease (CHD) continues to be the
leading cause of mortality and morbidity in the United
States [1] and is one of the top ﬁve most costly health
conditions to US employers, with total annual costs of
$130 billion [2,3]. Evidence-based guidelines issued by
the National Cholesterol Education Program (NCEP)
Adult Treatment Panel III (ATP III) underline the impor-
tance of hyperlipidemia treatment with an aggressive
LDL-C goal of <100 mg/dL for high risk patients [4].
In the changing statin marketplace and in multitier
formulary systems, it is important for managed care
plans to identify and utilize the most cost-effective
options among generic and branded statins. Lovastatin
(LOV) became available as a generic statin in 2002.
Pravastatin (PRV) and simvastatin (SMV) followed
with generic introduction in April and June 2006.
Because there are more choices for generic statins,
health-care administrators are considering various
statin formulary changes to optimize pharmacy budget
spend. An optimal statin formulary would provide
adequate clinical ﬂexibility to maximize clinical beneﬁt
to patients with efﬁcient use of health-care resources.
So it is important for health plan administrators to
identify the most cost-effective statin that may be a
generic statin for tier one and a more effective branded
statin that may be placed in tier two. A formulary
structure such as this can meet the objective of appro-
priate clinical choices, as well as cost-effective use of
statins. On the other hand, efﬁcient health-care deliv-
ery systems may consider using generic agents for
patients at low risk and a branded statin for patients
at higher risk of CHD. Nevertheless, there is limited
real-world evidence available comparing the effective-
ness and cost-effectiveness of the speciﬁc generic and
branded statins to guide the formulary decision.
Clinical trials have clearly demonstrated that statin
therapy lowers LDL-C by 45% to 63% with rosuvas-
tatin (RSV) and 25% to 60% with other statins [5–7].
Moreover, randomized trials have shown that approxi-
mately 86% to 94% of patients attain NCEP ATP III
LDL-C goal with rosuvastatin therapy; fewer attain
goal with the other statins [6,7]. Nevertheless, obser-
vational studies from chart review of primary care
physician practice have revealed lower rates of statin
effectiveness and the number of patients achieving
treatment goals. For example, only 23% to 48% of
high-risk patients were reported to have attained their
LDL-C goal in these studies [8–10]. This paradox
between clinical trial-reported statin efﬁcacy and
actual clinical practice statin effectiveness highlights
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the need to better understand the comparative effec-
tiveness of statins in a real-world setting.
The objectives of the present study was to estimate
the effectiveness of rosuvastatin to other statins,
cost-effectiveness of RSV compared with atorvastatin
(ATV) (branded statins), and among SMV, PRV, and
LOV (generic statins) in patients treated in routine
clinical practice. Cost-effectiveness comparisons for
branded and generic statins were separately conducted
to aid in the formulary decision-making within a
typical US health plan or pharmacy beneﬁt manage-
ment organization where formulary structure is com-
prised of generic agent(s) in tier one and branded
agent(s) in tier two.
Methods
A retrospective study was conducted utilizing the
General Electric Medical System (GEMS) electronic
medical records database of patients who were treated
in outpatient physician practices in the United States.
The objectives of the study were to examine the effec-
tiveness of statin monotherapy in the clinical practice
setting by comparing RSV with ATV, SMV, PRV. and
LOV for reducing LDL-C and LDL-C goal attainment.
The analysis was conducted to determine whether the
most efﬁcacious (LDL-C lowering and NCEP ATP III
goal attainment) statin (RSV) as observed in clinical
trials is the most effective statin in the real-world
setting as well. Similarly, the analysis determined if the
most efﬁcacious (LDL-C lowering and NCEP ATP III
goal attainment) generic statin (SMV), as observed in
clinical trials, is also more effective than other generic
statins (PRV, LOV) in the real-world clinical practice.
Cost-effectiveness was assessed among branded statins
and generic statins separately. LOV was selected as the
reference generic statin because it had a more stable
acquisition cost because it has been on the market
longest.
Patients receiving ﬂuvastatin, the least efﬁcacious
statin, were too few for meaningful analysis (<4% of
the statin users), and were excluded from the analysis.
Recently, a ﬁxed dose combination of SMV and
ezetimibe became available; however, it was not
included in this study because the number of eligible
patients receiving this ﬁxed dose combination was
relatively small for reliable effectiveness estimates.
Patients who were newly prescribed statin therapy
during August 2003 to May 2005 and had no prior
prescription for any dyslipidemic medication, includ-
ing bile acid sequestrants, ﬁbrin, niacin, ezetimibe, or a
statin, in the preceding 12 months were included in the
study. Titration of statin therapy was allowed, but
patients switching to other statins during the study
period were excluded. Patients had to be continuously
enrolled (i.e., active in physician’s practice) for a
minimum of 15 months; 12 months prior to and
3 months postinitiation of statin monotherapy. Addi-
tionally, patients were required to have a minimum
of 90-day supply of statin therapy (either a 90-day
prescription or three 30-day prescriptions) and lipid
results within 90 days prior to and greater than
30 days after initiating statin therapy. The lipid values
closest to the date of statin therapy initiation was
deﬁned as the baseline lipid measure. The follow-up
lipid value was deﬁned as the average of all lipid mea-
sures during the follow-up period, from 30 days after
initiation of statin therapy to the date of the last statin
prescription at time of discontinuation or end of study
(i.e., August 2005). Therapy discontinuation was
deﬁned as the lack of a prescription or reﬁll order
within 1.5 times the prescription days supply. Thus, if
a 30-day statin supply was ordered, then the prescrip-
tion must be reﬁlled or a new order written within
45 days of the initial prescription to consider the
patient persistent on statin therapy.
Two effectiveness outcomes were assessed: 1)
percent reduction in LDL-C; and 2) percentage of
patients attaining NCEP ATP III LDL-C goal. The
outcome measures were computed for each individual
statin. For LDL-C goal attainment assessment, patients
were stratiﬁed based upon NCEP CHD risk groups [4].
CHD and CHD risk equivalent was deﬁned as myo-
cardial infarction, ischemic heart disease, acute coro-
nary syndrome, cerebral vascular accident, transient
ischemic attack, peripheral vascular disease, abdomi-
nal aortic aneurysm, angina pectoris, atherosclerosis,
and diabetes mellitus. The GEMS database did not
contain information on inpatient procedures. A count
of risk factors was done to assign patients not assigned
to the CHD or CHD risk equivalent category to mod-
erate or low CHD risk. Moderate CHD risk patients
were deﬁned by the presence of two or more CHD risk
factors, including current cigarette smoking, hyperten-
sion diagnosis or blood pressure 140/90 mmHg,
low high-density lipoprotein cholesterol (HDL-
C) < 40 mg/dL, and age 45 for men and 55 for
women. Low-risk patients were deﬁned as those with
one or no CHD risk factors.
Because inpatient procedure data and data from
nonprimary care settings were not available in the
database, there was potential that some high-risk
patients were misclassiﬁed into the moderate risk cat-
egory due to missing information on inpatient proce-
dures. The fact that physicians started these patients
with LDL-C < 130 mg/dL on a statin treatment
was considered a strong indicator of their underlying
high risk status or a more aggressive LDL-C target
goal (<100 mg/dL). The LDL-C goal was deﬁned
as <100 mg/dL for high-risk patients, as well as
moderate-risk patients who had statin therapy
started, and baseline, untreated LDL-C levels
<130 mg/dL. Moderate risk patients with LDL-C
130 mg/dL at baseline were assigned a goal of
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<130 mg/dL. Low-risk patients were assigned a target
goal of <160 mg/dL.
Effectiveness Analysis
Multivariate linear and logistic regression analyzes
were conducted to adjust the effectiveness estimates for
baseline characteristics of age, sex, smoking, hyperten-
sion, CHD, systolic blood pressure, baseline LDL-C,
and therapy duration. The LDL-C goal attainment
analyzes were stratiﬁed by CHD risk level, high plus
moderate risk, and low risk. Logistic regression models
were used to estimate the probability of attaining goal
with different statins, and the sample mean of pre-
dicted probabilities was used as an estimate of the
expected rate of goal attainment adjusted for patient
characteristics. All statistical analyzes were conducted
using SAS Version 9.1 (SAS Institute, Inc., Cary, NC).
Cost-Effectiveness Analysis
A decision analysis, model-based cost-effectiveness
analysis was employed to estimate the incremental cost
relative to incremental effectiveness for the three group
comparisons. First, cost-effectiveness was computed
for the branded statins, RSV and ATV. Second, cost-
effectiveness was estimated comparing LOV to SMV
and PRV. LOV was used as the reference generic statin
because it has been a generic product the longest, with
a stable market price. The third comparison estimated
cost-effectiveness between the most cost-effective
branded statin and the most effective generic statin
while accounting for rebates on branded statins and
different patient copayments between branded and
generic statins.
The analysis employed a payer perspective with
direct medical costs only and time horizon of 1 year.
Resource-use parameters were based upon actual uti-
lization observed in the study cohort and included
annualized statin costs and the cost of titration (includ-
ing additional physician visits and drug wastage). The
costs of lipid panel and safety monitoring tests were
not included because their frequencies were nearly
identical across the statin user groups. Routine physi-
cian visits were also not included because there was no
anticipated difference in utilization among the statins
[11]. Unit costs were based on Medicare reimburse-
ment rates for physician visits associated with titration
of the statins (measured as the average of the 2006
Medicare Physician Fee Schedule for 99212 and
99213, or $60) [12]. Unit drug costs were based on the
wholesale acquisition cost (WAC) of statins as of May
2006 [13]. The base case drug price was $2.63 for RSV
(all doses), $2.31, and $3.30 for ATV (10 and 20 mg
and higher doses, respectively), $1.87, $2.51, and
$4.37 for SMV (5, 10, and 20 mg or higher doses,
respectively), $2.86, $2.90, and $4.26 for PRV (10, 20
and 40 mg or higher doses, respectively), and $0.62,
$1.10, and $1.97 for LOV (10, 20, and 40 mg, respec-
tively). Patient-level effectiveness parameters were
taken from the multivariate regression models, and
included percentage reduction in LDL-C and achieve-
ment of ATP III LDL-C goal.
All cost-effectiveness models were estimated using
TreeAge Pro Healthcare (TreeAge Software, Inc.,
Williamstown, MA). Key parameters were subjected to
extensive sensitivity analyzes [14,15], with particular
attention to the drug cost inputs, given uncertainty
about future generic statin prices as competition
among generic manufacturers intensiﬁes. A threshold
analysis [16] was performed for willingness-to-pay
equal to zero to determine the price point at which
SMV or PRV have the same cost per unit of effective-
ness as LOV utilizing generic LOV pricing. Because
SMV and PRV are new generic agents, competitive
pricing has not occurred yet. Nevertheless, this land-
scape will change as more manufacturers produce
these generic products, driving the price lower among
all generic statins. Thus, the threshold analysis pro-
vided the WAC discount price needed for SMV and
PRV to be as cost-effective as LOV. Also, different
levels of patient copayment ($5 generic/$15 brand,
$10 generic/$25 brand, and $10 generic/$30 brand)
were applied in the sensitivity analysis to determine the
actual threshold price for generic SMV from a payer
perspective after accounting for patient costs.
Results
The eligible study population consisted of 10,421
patients: 541 on RSV, 6383 ATV, 2232 SMV, 705
PRV, and 560 LOV. Several characteristics differed
among the patients on statins. RSV patients were
younger (P < 0.002) and had a higher baseline LDL-C
(P < 0.001) than other statin patients (Table 1).
Because the baseline LDL-C level was higher for RSV
patients, these patients were further from attaining
ATP III goals and required a greater LDL-C reduction
than other statin patients. RSV patients also had a
signiﬁcantly shorter length of statin therapy (183 days)
than other patients (239–259 days), P < 0.001. The
average daily dose of statin was signiﬁcantly lower
(P < 0.05) for RSV (11.6 mg) versus other statins
(17.2–34.8 mg) (Table 1).
Change in Lipid Parameters
The unadjusted and adjusted percent change in LDL-C
for each statin is reported in Table 2. RSV patients
had the greatest observed decrease in LDL-C, with an
average -32.5% reduction compared with -14.3%
to -20.4% for other statin patients. Multivariate
analyzes adjusting for baseline differences in age, sex,
smoking, hypertension, CHD, systolic blood pressure,
baseline LDL-C, and treatment duration also demon-
strated that RSV patients had a signiﬁcantly larger
decrease (-31.6%) in LDL-C than patients using
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other statins (-13.9% to -21.9%). Total cholesterol
change among the statins was signiﬁcantly greater for
RSV users (observed mean change: -21.8%  19.7,
adjusted mean change: -18.9%  10.5) compared
with other statins (Table 2).
Among generic statins, the observed 18.0% reduc-
tion in LDL-C for SMV was signiﬁcantly greater than
PRV (-14.3%, P < 0.001), but was not different from
LOV (-20.0%) (Table 2). The observed LDL-C re-
duction for PRV was signiﬁcantly less than LOV
(P < 0.001). After adjustment for baseline characteris-
tics, average percent LDL-C reduction remained sig-
niﬁcantly greater for SMV compared with PRV
(P < 0.001). The adjusted percent LDL-C change
among SMV patients was not different from LOV
patients. PRV patients had signiﬁcantly less LDL-C
reduction after adjustment than LOV patients.
NCEP Goal Attainment
After adjustment in baseline characteristics, the odds
of attaining NCEP ATP III LDL-C goal among the
moderate/high-risk group were greatest with RSV
users (Table 3). The estimated percent of patients
attaining ATP III LDL-C goal was signiﬁcantly higher
(P-value  0.004) among RSV patients (76.1%) than
among ATV (72.6%), SMV (65.0%), PRV (57.6%)
and LOV (61.7%) patients (Table 3). There was no
signiﬁcant difference in goal attainment between rosu-
vastatin and other statins in the low-risk group, except
for PRV (90.5% of RSV attained goal vs. 79.5% of
PRV, P < 0.05).
Focusing on generic statins, LDL-C goal attainment
was signiﬁcantly greater among SMV patients than
PRV or LOV patients (P < 0.001, Table 3). For SMV,
65.0% of patients attained LDL-C goal compared to
57.6% of pravastatin and 61.7% of lovastatin
patients. There were signiﬁcantly more LOV patients
attaining LDL-C goal than PRV (P < 0.001).
Cost-effectiveness
Branded statins. In the base-case analysis of drug costs
(WAC pricing) and titration costs (physician visits),
RSV had the lower annualized cost ($1008) compared
with ATV ($1179) after adjusting for differences in
patient characteristics (Table 4). Utilizing the adjusted
LDL-C reduction (adjusted for baseline characteris-
tics), RSV had lower adjusted annualized cost per
unit of LDL-C reduction ($35). For incremental cost-
effectiveness, RSV dominated ATV for LDL-C reduc-
tion (Table 4). For LDL-C goal attainment, focusing
on patients in the moderate/high-risk group, the annu-
alized cost per additional moderate/high-risk patient
attaining goal was lower for RSV ($1401) (Table 5).
Table 1 Baseline characteristics of patients treated in clinical practice by statin therapy type
Characteristics Rosuvastatin Atorvastatin Simvastatin Pravastatin Lovastatin
Number of subjects 541 6383 2232 705 560
Age, years, mean SD 62 12 63 12* 67 11* 67 11* 68 11*
Male, % 45% 48% 51% 47% 41%
Coronary heart disease, % 11% 11% 11% 10% 10%
Diabetes, % 6% 5% 4% 3% 5%
Hypertension, % 45% 40% 41% 44% 45%
Initial dose, mg, mean (SD) 11.6 (6.2) 17.2 (12.8)* 23.9 (11.4)* 34.8 (14.7)* 24.1 (11.2)*
Therapy duration, mean (SD) 182.6 (116.7) 258.5 (159.1)* 253.9 (157.9)* 253.0 (156.7)* 238.6 (155.4)*
Baseline lipid parameters
LDL-C, mean SD 155.5 48.8 131.0 45.7* 126.8 43.8* 133.3 39.8* 145.1 40.1*
TC, mean SD 229.7 47.1 209.2 46.9* 203.1 43.6* 209.8 39.2* 223.0 41.8*
HDL-C, mean SD 49.7 13.6 51.3 13.5* 52.2 14.1* 52.2 13.8* 54.1 14.7*
TG, mean SD 170.5 92.8 151.3 82.6* 147.0 80.3* 145.1 74.4* 147.2 77.9*
*P-value < 0.05 for comparison to rosuvastatin.
LDL-C, low-density lipoprotein cholesterol;TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol;TG, triglycerides.
Table 2 Mean change in lipid parameters by statin type
Lipid parameter
Rosuvastatin
N = 541
Mean (SD)
Atorvastatin
N = 6383
Mean (SD)
Simvastatin
N = 2232
Mean (SD)
Pravastatin
N = 705
Mean (SD)
Lovastatin
N = 560
Mean (SD)
% LDL-C change -32.5 (27.7) -20.4* (28.1) -18.0* (27.3) -14.3*†‡ (23.2) -20.0* (21.0)
% LDL-C change adjusted§ -31.6 (16.8) -21.9* (16.8) -19.1* (16.8) -13.9*†‡ (16.8) -18.0* (16.8)
% Total Cholesterol change -21.8 (19.7) -14.6* (18.8) -11.1* (17.5) -10.5* (14.5) -13.1* (14.4)
% Total cholesterol change adjusted§ -18.9 (10.5) -14.5* (10.5) -11.9* (10.5) -10.3* (10.5) -11.2* (10.5)
*P-value 0.001 as compared to rosuvastatin.
†P < 0.001 for lovastatin compared to pravastatin.
‡P < 0.001 for simvastatin compared to pravastatin or lovastatin.
§Mean change adjusted for age, sex, smoking, hypertension, CHD, systolic blood pressure, baseline LDL-C, and treatment duration.
LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease.
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RSV also dominated (less costly and more effective)
ATV for LDL-C goal attainment in high and moderate-
risk patients.
Generic statins. For generic statins, LOV, as the least
expensive generic statin, was utilized as the reference
and the threshold discount needed to achieve equiva-
lent cost-effectiveness across the generic statins was
estimated. PRV must be discounted by 71% (1-
threshold discount) of current WAC price to achieve
equal cost-effectiveness as LOV, and SMV must be
discounted by 61% to achieve equivalent cost-
effectiveness as LOV for lowering LDL-C (Table 4).
Similarly, for moderate/high-risk patients, PRV must
be discounted by 65.6% and SMV by 62% of current
WAC price to achieve equivalent cost-effectiveness as
LOV for ATP III LDL-C goal attainment (Table 5).
Most cost-effective branded statin versus most effective
generic statin. It is assumed that as more manufactur-
ers of generic SMV emerge, its price may decline
steeply, making it more economically attractive to
health plans. As a result, a comparison of the most
cost-effective branded statin, RSV, to the most effective
(and soon to be much cheaper) generic statin, SMV,
may be of signiﬁcant interest to decision-makers.
As noted above, given that drug acquisition costs
are a substantial component of overall drug treatment
costs, cost-effectiveness assessments are highly depen-
dent on acquisition cost assumptions. If the generic
price discount from the current WAC for SMV is
allowed to vary, a threshold discount can be identiﬁed,
at which RSV is preferred to generic SMV by a payer
willing to pay nothing for incremental effective-
ness (willingness-to-pay = 0). As shown in Table 6,
Table 3 Odds ratios and 95% conﬁdence intervals for attaining ATP III LDL-C goal among patients with high/moderate CHD risk
ATP III LDL-C goal
attainment*
Rosuvastatin
N = 309
Atorvastatin
N = 2698
Simvastatin
N = 929
Pravastatin
N = 354
Lovastatin
N = 303
Odds ratio (95%CI) — 0.72 (0.53–0.96) 0.49 (0.38–0.64) 0.26 (0.20–0.36) 0.31 (0.23–0.44)
Adjusted percentage attain LDL-C goal 76.1 (8.2) 72.6 (8.3)† 65.0 (9.3)† 57.6 (10.1)†‡§ 61.7 (9.5)†‡
*All comparisons are with rosuvastatin and adjusted for baseline differences in age, sex, smoking, hypertension, CHD, systolic blood pressure, percent LDL-C reduction needed
to reach goal, and treatment duration.
†P < 0.001.
‡P < 0.001 for simvastatin compared with pravastatin or lovastatin.
§P < 0.001 for lovastatin compared with pravastatin.
ATP III,Adult Treatment Panel III; LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease.
Table 4 Base case cost per patient per LDL-C reduction for branded and generic statins for all patients
Statin therapy Effectiveness % LDL-C change* Annualized cost†
Mean cost-effectiveness
ratio
Incremental
cost-effectiveness ratio
Branded statins
Rosuvastatin -31.6% $1008 $35 —
Atorvastatin -21.9% $1179 $54 Dominated
Generic statins Threshold discount‡
Lovastatin -18.0% $632 $35 1.00
Pravastatin -13.9% $480 $35 0.286
Simvastatin -19.1% $661 $35 0.389
*Mean change adjusted for age, sex, smoking, hypertension, CHD, systolic blood pressure, baseline LDL-C, and treatment duration.
†Nondrug costs were on average $7–$25/year.
‡Threshold discount was the price at which generic simvastatin or generic pravastatin have the same cost per unit of effectiveness as lovastatin for willingness-to-pay = 0.
LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease.
Table 5 Base case cost per patient attaining ATP III LDL-C goal for patients of moderate/high CHD risk
Statin therapy
Effectiveness % attain
LDL-C goal* Annualized cost†
Mean cost-effectiveness
ratio
Incremental
cost-effectiveness ratio
Branded statins
Rosuvastatin 76.1% $1066 $1401 —
Atorvastatin 72.6% $1195 $1646 Dominated
Generic statins Threshold discount‡
Lovastatin 61.7% $632 $1025 1.00
Pravastatin 57.6% $591 $1026 0.344
Simvastatin 65.0% $667 $1027 0.379
*Adjusted for baseline differences in age, sex, smoking, hypertension, CHD, systolic blood pressure, percent LDL-C reduction needed to reach goal, and treatment duration.
†Nondrug costs were on average $7–$25/year.
‡Threshold discount was the price at which generic simvastatin or generic pravastatin have the same cost per unit of effectiveness as lovastatin for willingness-to-pay = 0.
ATP III,Adult Treatment Panel III; LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease.
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focusing on LDL-C reduction, generic SMV would
have to be discounted by at least 58.3% [that is,
(1 - 0.417) ¥ 100] to be preferred when generic/
branded copays are $10/$25. The threshold discount
decreases as the generic/branded copay differential
narrows and increases if the differential expands—the
threshold discount is 54.7% given $5/$15 copay tiers,
and is 61.8% given $10/$30 copay tiers. Shifting the
focus to LDL-C goal attainment among moderate
and high-risk patients, the threshold discount is 59.2%
given generic/branded copays of $10/$25, compared
with 58.1% for $5/$15 copays and 61.6% for $10/$30
copays. In the low-risk group, considering no differ-
ence in LDL-C goal attainment between RSV and
SMV, SMV would be cost-effective if the average dose
weighted cost is below that of RSV.
Discussion
RSV was more effective than other statin monothera-
pies in lowering LDL-C (-31.6% change) and total
cholesterol (-18.9% change) in patients treated in a
real-world clinical setting. Importantly, RSV was also
more effective in getting moderate/high-risk patients to
attain NCEP ATP III LDL-C goal as compared with
other statins at an average daily dose lower than other
statins. A signiﬁcantly greater proportion of moderate
and high-risk patients using RSV (76%) were esti-
mated to achieve LDL-C goal than those using other
statins (57.6–72.6%).
RSV provided greater treatment effectiveness at
lower treatment costs than ATV for patients in clinical
practice in both LDL-C reduction and NCEP goal
attainment. Thus, in base case models, RSV dominated
ATV, because ATV was less effective and more costly
than RSV. The implications of these ﬁndings are impor-
tant for managed care decision-makers. Payers may
achieve substantial cost savings and greater effective-
ness by using RSV rather than ATV, depending upon
the actual acquisition prices. Thus, our ﬁndings
provide evidence for formulary decisions for the most
effective and cost-effective branded statin.
For generic statins, ATV and LOV had similar
LDL-C reduction, but SMV had signiﬁcantly more
patients attaining LDL-C goal than LOV or PRV.
Thus, SMV was the more effective generic agent.
Regarding the more cost-effective generic, SMV
generic price would need to be discounted by about
61% to 62% of current WAC price for it to be cost-
effective for payers to utilize as the most effective and
least costly generic statin.
Furthermore, our ﬁndings indicate that comparing
the most cost-effective branded (RSV) and generic
(SMV) statins, RSV was more cost-effective than
generic SMV until SMV WAC price was discounted by
at least 55% to 62% for cost/LDL-C reduction, and by
at least 58% to 62% for cost/ATP III goal attainment
among high/moderate-risk patients. The price of
generic SMV has fallen as more generic manufacturers
enter the market. Assuming that approximately 10
generic manufacturers of SMV are anticipated by the
end of 2007, based on an FDA analysis of the associa-
tion between relative price and number of generic
manufacturers [17], the price of generic SMV may fall
to 26% of its branded price (or a 74% discount).
Anecdotal information indicates that some payers may
even be purchasing generic SMV for $0.06 to $0.10
per tablet [18]. At this discount, SMV is less costly but
less effective than RSV. This has important implica-
tions for physicians and decision-makers, because for
patients who need a less effective agent, a generic agent
like SMV may be optimal, but patients who need a
more effective agent to reduce LDL-C and attain goal,
then RSV may provide an attractive option from both
an effectiveness and cost-effectiveness viewpoint.
ATV will go off patent in several years, and this may
result in the availability of ATV at a reduced cost. In
that future scenario, using the same methodology as
employed for generic SMV, RSV would be more cost-
effective than off-patent ATV until ATV WAC price
was discounted by at least 42% to 56% for cost per
LDL-C reduction, and by at least 39% to 49% for cost
per LDL-C goal attainment, depending upon copay-
ment level.
The cost-effectiveness estimates (branded and
generic) were based on aggregate statin doses and
aggregated prices across doses. Because some statins
have higher prices for higher doses, this was accounted
for in the analysis. Thus, health plans interested in
drawing comparisons to these estimates may need to
examine costs across doses by weighing the cost by
dose. Dose-to-dose comparisons were not feasible due
to small number of patients with different doses.
Several quality of care initiatives utilize the NCEP
LDL-C goals, thus it is important that MCOs focus on
lipid management to assist patients in attaining their
LDL-C goal. The National Committee for Quality
AssuranceHealth Plan Employer Data and Information
Set benchmarks the quality of care provided by
managed care organizations for patients after an acute
cardiovascular event based upon the proportion of
Table 6 Threshold generic simvastatin price for different
patient copayment levels
Patient Copayment
Threshold generic simvastatin price as
compared to current WAC*
LDL-C reduction ATP III LDL-C goal†
$5 generic/$15 brand 0.453 0.419
$10 generic/$25 brand 0.417 0.408
$10 generic/$30 brand 0.382 0.384
*Generic simvastatin price threshold above which rosuvastatin is preferred at
willingness-to-pay = 0.
†Moderate/high-risk group.
WAP,wholesale acquisition cost;ATP III,AdultTreatment Panel III; LDL-C, low-density
lipoprotein cholesterol; CHD, coronary heart disease.
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patients achieving NCEP goals [19]. Additionally,
several pay-for-performance programs are currently
rewarding physicians who treat their patients inten-
sively and get them to NCEP target goals (http://
www.iha.org/P4POVIEW.html, last accessed on
January 30, 2006) [20].
This study is unique because it is based on actual
clinical practice. The LDL-C reduction and NCEP goal
attainment were estimates among patients from differ-
ent physician ofﬁces on their usual care regimen rather
than patients selected and randomized in a clinical
trial. Our effectiveness estimates represent the actual
ﬁndings from patients treated in the community;
largely by primary care physicians (85% of practices
were primary care). Results from our study are similar
to investigations that quantiﬁed the efﬁcacy [21–23]
and cost-effectiveness [11,24] of statin therapy from
clinical trial data. RSV has been shown to be the most
efﬁcacious monotherapy statin in the clinical trial
setting [25], and we found RSV to be the most effective
of all monotherapy statins in clinical practice. Similar
to our ﬁndings, Benner [11] found RSV to be the most
cost-effective, and dominated ATV, PRV, and SMV
under the base case and several alternative scenarios
using data derived from clinical trial data. Bullano
showed that a greater percent of patients reached
NCEP ATP III LDL-C goal with RSV compared with
all other statins for high and moderate-risk patients
[26]. Our study conﬁrmed this greater effectiveness
of RSV for LDL-C reduction and goal attainment as
compared with other statins.
The study ﬁndings should be interpreted in light of
several limitations. The study population is comprised
of patients treated by physicians who utilize an elec-
tronic medical record system (GEMS) in their routine
clinical practice. Although the population includes
over 3000 physicians across the United States, there
may be differences in clinical practice patterns between
physicians who utilize GEMS and physicians who are
not electronically equipped. Moreover, the study phar-
macy data is the physician prescription order and not
pharmacy dispensing data indicating that the prescrip-
tion was ﬁlled. Hence, the assumption was made that
all statin prescription orders were ﬁlled by the patient.
To eliminate bias from this assumption, all patients
had to have at least 90 days of statin therapy to be
included in the study (i.e., at least three statin prescrip-
tions or one prescription with three reﬁlls). Neverthe-
less, the rate of therapy compliance is unknown and
may increase the variance in the lipid values. Also,
combination statin therapy was not included in this
study because of the study time period (before com-
bination therapy was widely available) and small
number of patients prescribed combination therapy.
An additional limitation is the lack of inpatient
procedure data in the GEMS database. Patients with
angioplasty, coronary artery bypass graft, and other
revascularization procedures are classiﬁed as high-risk
patients according to NCEP ATP III guidelines [4].
These patients could not be distinguished in our
dataset, thereby reducing the size and composition of
our high-risk group. To compensate for the lack of
procedure data, the high and moderate-risk groups
were combined. Costs were estimated using published
WAC for drugs and Medicare reimbursement rates for
physician visits and lab tests. These costs may not
reﬂect the actual costs negotiated by managed care
organizations, but wide variation in these parameters
were tested. Costs associated with adverse drug events,
and routine physician visits were excluded, but these
were not expected to differ across treatment groups
and therefore would not have affected the incremental
cost-effectiveness analysis. The analysis had a 1-year
time horizon and thus examined short-term endpoints
(LDL-C reduction and ATP III goal attainment) instead
of long-term outcomes such as cost per life-year gained
or cost per avoided CVD event. A longer follow-up
period or analytic model would be required to estimate
the long-term outcomes.
A meta-analysis of 14 randomized trials of statin
therapy indicated that statins safely reduced the 5-year
incidence of major coronary events, coronary revascu-
larization, and stroke by about one-ﬁfth per mmol/l
(39 mg/dL) reduction in LDL-C [27]. This analysis
found an approximately linear relationship between the
absolute reductions in LDL-C achieved and the propor-
tional reductions in the incidence of coronary and other
major vascular events, and those larger LDL-C reduc-
tions produced larger reductions in vascular disease
risk. These results cannot be directly applied to the
current study ﬁndings because it is not a randomized
trial and there are obvious differences in inclusion
criteria and follow-up period between the trials
included in the meta-analysis as compared with the
current observational study. Nevertheless, one can use
the results of the meta-analysis to arrive at a general
guidance of the expected beneﬁts in terms of avoided
cardiovascular events. Extrapolating to the study’s
50.5 mg/dL average absolute reduction in LDL-C for
patients with RSV, it could be estimated that continued
RSV therapywould reducemajor cardiovascular events
by one-fourth. Similar estimates can be arrived at for
other statins in this study or for differences in LDL-C
reduction observed between different statins.
In conclusion, the ﬁndings indicated that RSV is
more effective and less costly than ATV, providing
evidence for the branded statin of choice for formulary
inclusion in second tier. As generic prices for SMV and
PRV stabilize, it is likely that generic SMV will be the
most cost-effective generic statin based on the better
effectiveness and low cost of generic SMV [18]. To
facilitate effective and efﬁcient management of patients
with dyslipidemia, a tiered formulary could include
generic SMV or PRV in ﬁrst tier (depending upon level
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of discount to WAC at multisource generic pricing)
and RSV in second tier. Compared with ATV, RSV
provides additional clinical beneﬁts (better percentage
LDL-C reduction and goal attainment) and also results
in cost savings. Compared with generic SMV, RSV
offers substantial additional LDL-C reduction and
NCEP goal achievement, but at an additional cost.
Further understanding of the value that clinicians and
payers place on the additional clinical beneﬁts (getting
additional percentage LDL-C reduction and additional
patients to goal) would determine the economic attrac-
tiveness of RSV as compared with generic SMV for
management of dyslipidemia in this at-risk patient
population.
Source of ﬁnancial support: This research was sponsored by
AstraZeneca LP.
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